New White Paper - Read AAM Report on Drug Shortages

Tom Shea

AAM Board Member
CEO, Meitheal Pharmaceuticals
Tom Shea, CEO, Meitheal Pharmaceuticals
Tom Shea
Meitheal Pharmaceuticals

Tom Shea is the CEO of Meitheal Pharma, a position he has held since its inception in 2017. In addition, Tom is also the President of Xentria, Inc., a biotech company focused on novel biologics and biosimilars, which was established in April 2020. He has over 17 years’ experience in the generic pharma industry.

Prior to joining Meitheal and Xentria, Tom was Vice President of Global Alliance Management for Sagent Pharmaceuticals and was responsible for global partnerships, supply chain and product development. Before his work at Sagent, Tom held various roles at APP, now Fresenius Kabi North America, in Commercial Operations and Business Development, focusing on Portfolio Management and National Accounts. Tom started his pharmaceutical career at Fougera.

Tom earned an M.B.A. from Notre Dame University and a B.A. in Philosophy from Marquette University.

Latest Tweets

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.